Literature DB >> 26370906

Niacin as antidyslipidemic drug.

Ulrich Julius1,1.   

Abstract

Niacin is an important vitamin (B3) that can be used in gram doses to positively modify pathogenetically relevant lipid disorders: elevated LDL cholesterol, elevated non-HDL cholesterol, elevated triglycerides, elevated lipoprotein(a), and reduced HDL cholesterol. This review reports the latest published findings with respect to niacin's mechanisms of action on these lipids and its anti-inflammatory and anti-atherosclerotic effects. In the pre-statin era, niacin was shown to have beneficial effects on cardiovascular end-points; but in recent years, two major studies performed in patients whose LDL cholesterol levels had been optimized by a statin therapy did not demonstrate an additional significant effect on these end-points in the groups where niacin was administered. Both studies have several drawbacks that suggest that they are not representative for other patients. Thus, niacin still plays a role either as an additive to a statin or as a substitute for a statin in statin-intolerant patients. Moreover, patients with elevated triglyceride and low HDL cholesterol levels and patients with elevated lipoprotein(a) concentrations will possibly benefit from niacin, although currently the study evidence for these indications is rather poor. Niacin may be useful for compliant patients, however possible side effects (flushing, liver damage) and contraindications should be taken into consideration.

Entities:  

Keywords:  adverse effects; cardiovascular end-points; effets indésirables; intervention studies; lipid disorders; niacin; niacine; paramètres d’évaluation cardiovasculaires; troubles lipidiques; études interventionnelles

Mesh:

Substances:

Year:  2015        PMID: 26370906     DOI: 10.1139/cjpp-2014-0478

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  6 in total

1.  Loss of neurexin-1 in Drosophila melanogaster results in altered energy metabolism and increased seizure susceptibility.

Authors:  Kyra A Levy; Eliana D Weisz; Thomas A Jongens
Journal:  Hum Mol Genet       Date:  2022-10-10       Impact factor: 5.121

Review 2.  Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection.

Authors:  Ulrich Julius
Journal:  Med Devices (Auckl)       Date:  2016-10-13

Review 3.  Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies.

Authors:  Katarzyna Rygiel
Journal:  Curr Cardiol Rev       Date:  2018-03-14

Review 4.  Implications of altered NAD metabolism in metabolic disorders.

Authors:  Keisuke Okabe; Keisuke Yaku; Kazuyuki Tobe; Takashi Nakagawa
Journal:  J Biomed Sci       Date:  2019-05-11       Impact factor: 8.410

5.  Long-term consumption of energy drinks induces biochemical and ultrastructural alterations in the heart muscle.

Authors:  Camelia Munteanu; Corina Rosioru; Corneliu Tarba; Camelia Lang
Journal:  Anatol J Cardiol       Date:  2018-05       Impact factor: 1.596

Review 6.  Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients.

Authors:  Ulrich Julius
Journal:  J Cardiovasc Dev Dis       Date:  2018-05-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.